ArticleResearch and practice in thrombosis and haemostasis2026
Coagulation assays for assessing the bypassing of factor Xa direct oral anticoagulants using VMX-C001.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From empirical hemostasis to precision reversal: clinical challenges, technological innovations, and individualized strategies in anticoagulant-associated bleeding.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Factor (F)Xa direct oral anticoagulants (DOACs) require rapid reversal in patients with serious bleeding or needing urgent surgery/interventions. VMX-C001 is a recombinant human FX variant under development as an FXa DOAC bypassing agent. Objectives: This study aimed to develop and evaluate the sensitivity of 2 modified commercially available coagulation assays-dilute prothrombin time (dPT) and dilute Russell viper venom time (dRVVT)-to assess coagulation with FXa DOACs with/without VMX-C001. Methods: Citrated platelet-poor plasma samples were obtained from healthy volunteers. Assay evaluation was performed using undiluted and 2.5× diluted plasma for dPT and 3× and 4× diluted plasma for dRVVT in the absence and presence of apixaban (100 or 250 ng/mL) and/or VMX-C001 (30 μg/mL). Additionally, dPT/dRVVT were measured in plasma spiked Results: Both modified dPT and dRVVT assays were highly sensitive to FXa DOACs, showing dose-dependent prolongation of clotting time, which was fully restored when VMX-C001 or andexanet (higher concentrations) was present in the plasma. Using both assays, clotting time from healthy subjects and nursing home residents receiving FXa DOACs correlated strongly with plasma drug concentrations. Conclusion: dPT and dRVVT assays can serve as surrogate end points in studies of VMX-C001 and can also be used to monitor FXa DOAC anticoagulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.